OTC:CC - Ocumetics Announces December 20 2023 Webinar regarding Successful Completion of Animal Study
(TheNewswire)
Calgary, Alberta - TheNewswire - December 15, 2023. - Ocumetics Technology Corp. (“ Ocumetics ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) , a pioneer in the field of ophthalmic innovation, announcesa webinar to discuss the successful completion of its biocompatibilityanimal study and its upcoming first-in-human study, anticipated tocommence in Q1 2024 in the Dominican Republic.
Dean Burns, CEO of Ocumetics and 27-year Alcon veteran,will lead the presentation.
Join the webinar to:
-
Learn more about the significance of thebiocompatibility animal study;
-
Learn more about the upcoming first-in-human study; and
-
Ask questions regarding the Ocumetics AccommodatingLens and the company’s plans.
Details are as follows:
Date: December 20, 2023
Time: 18:00 EST
RSVP: https://ocumetics.com/webinar-december-20-2023/
About Ocumetics
Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO),headquartered in Calgary, Alberta, Canada, is an innovator in the field of ophthalmic technology, dedicated todeveloping and commercializing advanced vision correction solutionsthat enhance the quality of life for individuals worldwide.
Ocumetics is in the preclinical study stage of agame-changing technology for the ophthalmic industry. In its pursuitof a next generation interocular lens solution, Ocumetics hasdeveloped the Ocumetics Accommodating Lens, an expandable intraocularlens that fits within the natural lens compartment of the eyepotentially to eliminate the need for corrective lenses. It isdesigned to allow the eye’s natural muscle activity to seamlesslyshift focus from distance to intermediate to near.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dean Burns
President and CEO
(817) 874-7564
Dayton Marks
Director
(778) 347-2500
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
Copyright (c) 2023 TheNewswire - All rights reserved.